How to Access Reblozyl in India Through Patient Support Programs

Living with transfusion-dependent blood disorders is associated with chronic anaemia and substantial physical and psychosocial burden, including anxiety, activity restriction, and disruption of daily, social, and work life. As a result, an important goal for patients and families is to reduce the need for blood transfusions while improving quality of life.^1,2

Reblozyl® (luspatercept) is one such therapy that has changed the treatment landscape for certain blood disorders by supporting healthier red blood cell production.³ Understanding what this medicine is, who it is meant for, and how it fits into long-term care is an important first step for patients considering it as part of their treatment journey.

Understanding Reblozyl and Who It Is For

Reblozyl is an injectable medicine used to treat anaemia (low haemoglobin levels) in certain blood disorders. It works by helping the body produce healthier red blood cells, thereby reducing the need for frequent blood transfusions.^3,4

Reblozyl is commonly prescribed for⁴:

• Adults with beta thalassemia who require regular red blood cell transfusions
• Adults with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (or myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis) who have failed erythropoiesis-stimulating agents and require regular red blood cell transfusions.

Your doctor determines whether Reblozyl is suitable for you based on factors such as diagnosis, transfusion burden, previous treatments and overall health.

Reblozyl Access in India: Current Options and Challenges

Since Reblozyl has not been approved in India, patients and their families may face these challenges while trying to access this drug⁵:

• Limited local availability
• High treatment costs

Because of these challenges, many eligible patients explore Patient Support Programs (PSPs) or Named Patient Programs (NPPs) to access Reblozyl legally and safely.

What are PSPs and NPPS?

PSPs are initiatives designed to help patients access innovative therapies by offering guidance and support and improving medication adherence; they may sometimes help reduce medical cost and hospitalization.⁶

An NPP is a regulated pathway that may allow a patient with a serious or life-threatening condition to receive a medicine that is not yet commercially available locally.⁷

It may be considered when⁷

• The condition is serious and no satisfactory alternative treatment exists.
• The patient cannot participate in a relevant clinical trial.
• The treating doctor believes the potential benefits outweigh the potential risks.

Medicines accessed through this route may still be under regulatory review in some regions. This means their full safety and effectiveness profile may still be evolving, and careful medical supervision is essential throughout treatment.⁷

Eligibility Criteria to Access Reblozyl Through Support Programs

Eligibility is assessed on a case-by-case basis. While criteria may vary slightly, patients typically need to

• Have a confirmed diagnosis for which Reblozyl is indicated
• Show evidence of transfusion dependence or inadequate response to standard therapy
• Be under the care of a qualified specialist (such as a haematologist)

Final eligibility is determined after review of medical records by the treating doctor and the access partner.

Step-by-Step Process to Apply for Reblozyl in India

Although the process may seem complex, it usually follows these steps⁸:

1. Consult Your Treating Doctor
   Your doctor evaluates whether Reblozyl is clinically appropriate for you.
2. Medical Documentation Review
   Relevant reports are compiled to support the access request.
3. Application Process
   The patient should submit Form 12A with supporting documents to the Central Drugs Standard Control Organisation (CDSCO)..
4. Regulatory Review
   The application is reviewed by CDSCO to ensure compliance with medical and regulatory requirements. After review, CDSCO issues Form 12B, typically within 1-2 working days.
5. Approval and Importation
   Once approved, the medicine is imported specifically for the named patient.
6. Treatment Initiation
   Reblozyl is administered under medical supervision as per the prescribed schedule.

Documents and Medical Reports Needed for Reblozyl Access

- From the physician⁷:

Prescription containing Medical Council of India registration number of the physician and the name, quantity and duration of treatment

- From the patient⁷:

Clinical records, ID/address proof

- From the supplier⁷:

An invoice or other statement showing the name and address of the manufacturer and the names and quantities of the drugs.

Having complete and up-to-date records helps avoid delays.

Costs, Funding Options and Financial Assistance Pathways

While accessing Reblozyl, expenses may include the medicine itself, importation, and ongoing monitoring.

Some assistance pathways may help eligible patients reduce out-of-pocket costs. These programs operate under strict legal and ethical guidelines. In certain situations, direct manufacturer-sponsored support may not be permitted, and patients may instead be guided toward independent, disease-specific charitable funds that provide need-based assistance.⁹

Your treating doctor and access partner can help explain expected costs and available support options before treatment begins.

Role of Your Treating Doctor and the Access Partner

Your treating doctor plays a central role by:

• Confirming medical eligibility
• Prescribing Reblozyl
• Monitoring safety and response to treatment

The access partner helps by:

• Managing paperwork and regulatory steps
• Coordinating importation and delivery
• Acting as a point of contact throughout the process

Together, they ensure treatment access remains ethical, legal and patient-focused.

Ongoing Monitoring, Safety and Follow-Up Once on Reblozyl

Before beginning therapy, consider asking:

• What benefits can I realistically expect?
• What are the possible side effects?
• How long will I need treatment?
• What will the total cost be over time?

Clear communication helps build confidence and set realistic expectations.

Navigating Access with Rx4U

Accessing Reblozyl in India may require specific approvals and coordination. In India, programs such as Rx4U may support this process by coordinating documentation and regulatory steps in partnership with your treating doctor.

Speak with your specialist to understand whether Reblozyl and the appropriate access pathway are right for you.

Frequently Asked Questions

- Do I need a prescription to apply?
A valid prescription from a qualified specialist is mandatory.

- Can children receive Reblozyl?
Reblozyl is currently indicated for adults; your doctor can advise on suitability.

- Whom should I contact to start the process?
Begin by speaking with your treating doctor, who can connect you to the appropriate support pathway.

References:

- Gupta GK, Patidar G, Perez-Carrillo J, et al. Impact of red blood cell transfusion on patient’s quality of life: a comprehensive narrative review. Ann Blood. 2025;10:11.

- Drahos J, Boateng-Kuffour A, Calvert M, et al. Health-Related Quality-of-Life Impacts Associated with Transfusion-Dependent β-Thalassemia in the USA and UK: A Qualitative Assessment. Patient. 2024;17(4):421-439. doi:10.1007/s40271-024-00678-7

- Patel B, Patel P, Moosavi L. Luspatercept. In: StatPearls. StatPearls Publishing; 2025 Jan-. Updated October 14, 2024. Accessed February 10, 2026. https://www.ncbi.nlm.nih.gov/books/NBK560635/

- Prescribing Information. Celgene Corporation. 2020. Accessed February 11, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf

- Ministry of Health and Family Welfare, Government of India. National Policy for Treatment of Rare Diseases. 2017. Accessed February 11, 2026. https://www.mohfw.gov.in/sites/default/files/Rare%20Diseases%20Policy%20FINAL.pdf

- Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711-725. doi:10.2147/PPA.S101175

Expanded Access. FDA. September 8, 2025. Accessed February 11, 2026. https://www.fda.gov/news-events/public-health-focus/expanded-access

Central Drugs Standard Control Organisation. Procedures To Import Small Quantities of Drugs for Personal Use: Notice. Ministry of Health & Family Welfare, Government of India. February 19, 2015. Accessed August 25, 2025. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadConsumer/ProcedureforpermissiontoImportSmallQuantitiesofDrugsForPersonalUse_link.pdf

Kang SY, Sen A, Bai G, Anderson GF. Financial eligibility criteria and medication coverage for independent charity patient assistance programs. JAMA. 2019;322(5):422-429. doi:10.1001/jama.2019.9943

Note:

This information is provided for educational purposes only and is not a substitute for professional medical advice. Lokelma should only be taken under the guidance of a qualified healthcare provider. Patients should always consult their doctor or pharmacist for advice on diagnosis, treatment, and medication use, and should not make changes to their prescribed therapy without medical supervision.

Disclaimer:

Rx4U procures prescribed medicines directly from manufacturers or authorized distributors. It does not claim ownership of any trademarks and complies with the provisions of the Trademark Act, 1999, particularly Sections 30 and 30(1) concerning ‘Fair Use’. It solely facilitates access to new launches through named patient import.